Drug Dev
Tilt arms oncolytic viruses to enable T-cell therapies
Immunotherapy, currently the hottest show in town, provides a rich opportunity for biotechs with unique approaches to link up with cancer-focused giants as they look for optimal combinations to tackle hard-to-treat tumors. During BIO-Europe Spring 2018, Aino Kalervo, head of business management at Finnish startup Tilt Biotherapeutics, told Scrip how the company was looking for investors and potential partners to advance its lead oncolytic virus program TILT-123, which has already delivered promising proof of concept, into Phase I trials in solid tumors.